CARsgen Therapeutics, a Shanghai CAR-T company, was approved to start US trials of its fully human BCMA (B-Cell Maturation Antigen)-CAR-T therapy for patients with relapsed/refractory multiple myeloma. Four months ago, China’s NMPA approved a similar IND for CT053, and it has begun China clinical trials. So far, CT053 has been administered to 24 heavily pre-treated patients in the China trial. CARsgen said 87.5% of them showed a response, and 70.8% had a complete response. No patients had cytokine release syndrome higher than grade 2.
Source: China Biotoday